Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus

Scheen, André

doi:10.1007/s40262-014-0157-y

Cited by 42 publications

(31 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Целью исследования V. Kupčová и соавт. (2014) было изучение влияния ПН на фармакоки-нетику деглудека. Двадцати четырем пациентам, разделенным на 4 группы по 6 человек в зависимо-сти от уровня ПН (с нормальной функцией печени и классами ПН по Чайлд-Пью A, B и C), однократ-но вводили инсулин деглудек подкожно в дозе 0,4 ЕД/кг.…”

Section: лечение сахарного диабета у пациентов с циррозом печениunclassified

“…C. B. Giorda и соавт. (2014) представили данные литературного обзора, посвященного препаратам с инкретиновым эффектом, применяемым у пациентов с СД и нару-шением функции печени. Резюмируя обобщенные данные, авторы указали на недостаточный объем доказательств для применения данных препара-тов при ПН у пациентов с СД.…”

Section: лечение сахарного диабета у пациентов с циррозом печениunclassified

“…Исследова-ние Х. Zhang с соавт. (2014) имело целью устано-вить, улучшает ли метформин выживаемость паци-ентов с диабетом после установления диагноза ЦП. В период с 2000 по 2010 гг.…”

Section: лечение сахарного диабета у пациентов с циррозом печениunclassified

“…Целью исследования C. H. Yang и соавт. (2014) было выяснить, является ли СД независимым фактором риска кровотечений из варикозно расши-ренных вен пищевода. В проспективном исследова-нии приняли участие в общей сложности 146 пациен-тов с ЦП (75 с классом А по Чайлд-Пью, 40 -с классом В и 31 -с классом С).…”

unclassified

See 3 more Smart Citations

Diabetes Mellitus in Patients With Liver Cirrhosis: New Treatment Options

Моргунов¹

2017

Issled. prakt. med. (Print)

View full text Add to dashboard Cite

In economically developed countries, cirrhosis is one of the six leading causes of death at the age of 35–60 years and ranges from 14 to 30 cases per 100000 population. In the world 40 million people die of cirrhosis each year. At 6% of the population of the Russian Federation there is a diabetes mellitus. The combination of diabetes mellitus in patients with cirrhosis of the liver is a common comorbid pathology. Diabetes mellitusis a risk factor for the development of liver cirrhosis, and the incidence of combination of both diseases is quite high, although the frequency of occurrence varies. About 80% of patients with LC may have impaired glucose metabolism, and 30% have diabetes mellitus. Prospective studies have shown that diabetes is associated with an increased risk of developing hepatic complications and death in patients with cirrhosis of the liver. Diabetes mellitus increases the risk of complications of liver cirrhosis of any etiology (varicose veins of the esophagus, hepatic encephalopathy, hepatic-cell insufficiency) and subsequent survival. The incidence, frequency of hospitalizations and mortality from this combined pathology are very high. There are common mechanisms that provoke metabolic and autoimmune disorders in the development of chronic hepatitis and cirrhosis, leading to steatosis, insulin resistance, impaired glucose tolerance and the development of diabetes mellitus. There are certain features of the evaluation of the compensation of carbohydrate metabolism in patients with cirrhosis of the liver, anemia and impaired protein metabolism. Effective control of glycemia can have a beneficial effect on the treatment of these patients. However, few studies have evaluated the efficacy and safety of antidiabetic drugs and the effect of diabetes treatment on morbidity and mortality in patients with cirrhosis. Previously it was believed that in the presence of cirrhosis the only treatment remains insulin. At present, in connection with the emergence of modern groups of hypoglycemic drugs, as well as new approaches to the treatment of type 2 diabetes, this concept has radically changed. Unfortunately, the issues of correction of carbohydrate metabolism in patients with cirrhosis of the liver are practically not covered in the world literature. This article deals with the correction of carbohydrate metabolism in patients with cirrhosis and hepatocellular insufficiency of insulin analogs, biguanides, drugs with incretin effect — dipeptidyl peptidase‑4 inhibitors, agonists of glucagon-like peptide‑1, inhibitors of sodium-glucose cotransporter 2 diabetes. Particular attention is paid to the development of hepatocellular insufficiency and portal hypertension in patients with cirrhosis and type 2 diabetes, as well as processes for their prevention and insulin alternative correction methods.

show abstract

Section: лечение сахарного диабета у пациентов с циррозом печениunclassified

unclassified

See 2 more Smart Citations

Diabetes Mellitus in Patients With Liver Cirrhosis: New Treatment Options

Моргунов¹

2017

Issled. prakt. med. (Print)

View full text Add to dashboard Cite

show abstract

“…They are largely renally excreted and have not been shown to have significant hepatotoxicity. They have been used for the treatment of NAFLD and appear to be safe, but the data are limited, and hence no broad recommendation for their use can be made at the present time [54][55][56][57].…”

Section: Glucagon-like Peptide Mimeticsmentioning

confidence: 99%

Promoting a Healthy Lifestyle, Managing Hyperlipidemia, Diabetes Mellitus, Hypertension, and Immunizations in Patients with Cirrhosis

Nunes

Pungpapong

2015

Complications of Cirrhosis

View full text Add to dashboard Cite

Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment

Bækdal

Thomsen

Kupčová

et al. 2018

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Semaglutide is a human glucagon‐like peptide‐1 analog that has been co‐formulated with the absorption enhancer, sodium N‐(8‐[2‐hydroxybenzoyl] amino) caprylate, for oral administration. This trial (NCT02016911) investigated whether hepatic impairment affects the pharmacokinetics, safety, and tolerability of oral semaglutide. Subjects were classified into groups: normal hepatic function (n = 24), and mild (n = 12), moderate (n = 12), or severe (n = 8) hepatic impairment according to Child‐Pugh criteria, and received once‐daily oral semaglutide (5 mg for 5 days followed by 10 mg for 5 days). Semaglutide plasma concentrations were measured during dosing and for up to 21 days post‐last dose. Area under the semaglutide plasma concentration–time curve from 0–24 hours after the 10th dose (primary end point) and maximum semaglutide concentration after the 10th dose appeared similar across hepatic function groups. Similarly, there was no apparent effect of hepatic impairment on time to maximum semaglutide concentration (median range 1.0–1.5 hours) or half‐life (geometric mean range 142–156 hours). No safety concerns were identified in subjects with hepatic impairment receiving semaglutide. Reported adverse events were in line with those observed for other glucagon‐like peptide‐1 receptor agonists. There was no apparent effect of hepatic impairment on the pharmacokinetics, safety, and tolerability of oral semaglutide. The results of this trial suggest that dose adjustment of oral semaglutide is not warranted in subjects with hepatic impairment.

show abstract

Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus

Cited by 42 publications

References 71 publications

Diabetes Mellitus in Patients With Liver Cirrhosis: New Treatment Options

Diabetes Mellitus in Patients With Liver Cirrhosis: New Treatment Options

Promoting a Healthy Lifestyle, Managing Hyperlipidemia, Diabetes Mellitus, Hypertension, and Immunizations in Patients with Cirrhosis

Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment

Contact Info

Product

Resources

About